The approval of AKEEGA™ underscores the critical importance of genetic testing in managing prostate cancer. BRCA gene mutations are linked to more aggressive forms of cancer and can significantly affect treatment decisions and outcomes.

AKEEGA™ combines a PARP inhibitor with abiraterone acetate, administered alongside prednisone, marking a significant leap forward in precision medicine. The approval is based on the results of the Phase 3 MAGNITUDE study, which included the largest population of BRCA-positive patients in combination trials to date.

Learn More:https://www.janssen.com/fda-approves-akeega-niraparib-and-abiraterone-acetate-first-and-only-dual-action-tablet